Jolanta Magnuszewska

Dr. Jolanta Magnuszewska

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Analytica Chimica Acta
Verified
Journal Article
Closed access
JMJolanta Magnuszewska
Jolanta Magnuszewska
TKTadeusz Krogulec
Tadeusz Krogulec

11 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kruk
Katarzyna Kruk
MSMarta Szekalska
Marta Szekalska
EWEliza Wolska
Eliza Wolska
IMIwona Misztalewska-Turkowicz
Iwona Misztalewska-Turkowicz
KMKarolina Halina Markiewicz
Karolina Halina Markiewicz
Katarzyna WinnickaKatarzyna Winnicka
Katarzyna Winnicka
Background/Objectives: Enteric drug forms are developed to delay drug release to avoid drug degradation in the acidic environment of the stomach or to prevent irritation of the stomach mucosa. The bioavailability of posaconazole (POS) after oral administration depends on stomach pH and food intake. Delayed-release tablets and unmodified oral suspension are the POS formulations currently available on the market. The oral suspension formulation is characterized by highly variable bioavailability, which may significantly affect therapy effectiveness. Methods: In this study, multi-unit drug forms with delayed and sustained POS release were designed. Polymeric microparticles consisting of sodium alginate (ALG), methacrylic acid–ethyl acrylate copolymer (EUD), or both, were prepared using the spray-drying technique. The formulations that met the pharmacopoeia enteric release standards in the in vitro dissolution test were subjected to further in vitro evaluation via swelling and mucoadhesion assays, an antifungal activity test, attenuated total reflectance–Fourier transform infrared spectroscopy (ATR-FTIR), and thermal analysis. Results: It was shown that EUD formulations at concentrations of 5% and 6% provided enteric release, whereas ALG at 1.5% concentration exhibited a sustained, although not delayed, POS release profile. The optimal blended formulations (EAP15–EAP18), comprising 4% EUD with 1.5–2.0% ALG and either 1% or 4% POS, met the pharmacopoeia criteria for enteric dosage forms. Furthermore, these blends demonstrated the most favorable sustained-release profiles in the buffer phase, ranging from 2 to 3 h. The microparticles exhibited beneficial swelling and mucoadhesive properties, which are essential for prolonging contact with the intestinal mucosa; combined with antifungal properties. Conclusions: Obtained carrier may provide a promising preliminary basis for developing a multi-unit, sustained-release enteric dosage form for POS and future in vivo investigations.

29 January 2026 in Materials
Verified
Journal Article
Open access
PDF file
Świderski GrzegorzŚwiderski Grzegorz
Świderski Grzegorz
Marek JałbrzykowskiMarek Jałbrzykowski
Marek Jałbrzykowski
Monika KalinowskaMonika Kalinowska
Monika Kalinowska
MPMałgorzata Pawłowska
Małgorzata Pawłowska
GMGrzegorz Markiewicz
Grzegorz Markiewicz
JMJolanta Magnuszewska
Jolanta Magnuszewska
Polylactide (PLA) composites were prepared and doped with starch (10% by weight), and mineral salts used as mineral fertilisers (MgSO4, KNO3, Ca(NO3)2 and Ca3(PO4)2) were prepared. The content of the added fertilisers was 2% by mass in the composites. The tensile strength properties of the obtained composites were tested. The effect of the addition of fertilisers on the structure of polylactide was analysed using spectroscopic methods (FTIR and FTRaman). The thermal properties of the obtained composites were tested using thermogravimetry (TG/DTG) and differential scanning calorimetry (DSC). PLA composites with fertilisers were tested for biodegradability in two types of soil—field soil and horticultural soil—and in compost. Biodegradability was assessed based on the mass loss of biodegraded composites, spectroscopic tests and visual assessment of changes occurring in the composites. Tests were performed on the respiratory activity of microorganisms in the compost extract in which the tested composites were placed. The addition of mineral salts used in the tested composites significantly influenced the biodegradation rate of the composites. Mineral compounds (MgSO4, KNO3 and Ca(NO3)2) added to the PLA–starch composite improve its mechanical properties. It should also be noted that the addition of mineral salts to the prepared composites did not affect the chemical structure of polylactide. The addition of mineral salts to PLA also did not significantly affect its thermal properties, as demonstrated by DSC and TG thermal analysis.

29 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMarta Szekalska
Marta Szekalska
MTMonika Trofimiuk
Monika Trofimiuk
Ewelina PiktelEwelina Piktel
Ewelina Piktel
MSMałgorzata Sidewicz
Małgorzata Sidewicz
EWEliza Wolska
Eliza Wolska
Katarzyna WinnickaKatarzyna Winnicka
Katarzyna Winnicka
Background/Objectives: Vaginal administration enables optimal drug concentrations at the site of administration, but its effectiveness is limited by factors such as the vagina’s self-cleansing mechanisms and fluctuations in physiological conditions. Due to the difficulties in treating and the frequent recurrences of vaginal candidiasis, new drug formulations are required to ensure more effective therapy and sustained release of antifungal agents. Mucoadhesive vaginal sponges are a promising drug formulation providing prolonged release of the active ingredient and its contact with the vaginal mucosa. The application of polymers and their modifications plays a key role in the development of drug forms with unique and desired technological parameters. Methods: Therefore, the focus of this research was the development of a three-stage sodium alginate cross-linking technique based on polyelectrolyte complexes with gelatin and ɛ-poly-L-lysine, and additional ionic cross-linking with zinc ions, to obtain mucoadhesive vaginal sponges with an antifungal agent—luliconazole. The prepared formulations were evaluated for their pharmaceutical, mechanical, and mucoadhesive properties. In addition, antifungal and anti-biofilm action against Candida strains and compatibility with the vaginal VK2 E6/E7 epithelial cell line of the prepared sponges were assessed. Results: It was noted that the triple cross-linking process increased the mechanical properties of the developed sponges, improved mucoadhesive properties to vaginal mucosa of drug-loaded formulations, and demonstrated a sustained LUL release profile. Moreover, prepared sponges possessed improved antifungal and anti-biofilm effects against C. albicans, C. krusei, and C. parapsilosis. The prepared triple cross-linked formulations were biocompatible with the human vaginal VK2 E6/E7 epithelial cell line, depending on the exposure time and applied concentration. Conclusions: Triple cross-linked alginate sponges containing luliconazole were successfully prepared based on polyelectrolyte complexes with gelatin and ɛ-poly-L-lysine and additional ionic cross-linking with zinc ions. The triple cross-linking process of alginate improved the mechanical, mucoadhesive, and antifungal properties of the developed formulations.